Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders

• US 20080306070A1
• Filed: 09/22/2006
• Published: 12/11/2008
• Est. Priority Date: 10/04/2005
• Status: Abandoned Application

• Current Assignee: Bayer Schering Pharma AG (Bayer AG)
• Original Assignee: Bayer Healthcare AG (Bayer AG)
• Inventors: Perzborn, Elisabeth, Krahn, Thomas
• Application Number:
  US12/089,169
• Publication Number:
  US 20080306070A1
• Time in Patent Office: Days
• US Class Current: 514/236.8
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61K 31/538 ortho- or peri-condensed with carbocyclic ring systems
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/06 Antiarrhythmics

Abstract

The present invention relates to combinations of A) oxazolidinones of the formula (I),

with B) antiarrhythmics, processes for the production of these combinations, their use for the prophylaxis and/or treatment of diseases, and their use for the manufacture of medicaments for the prophylaxis and/or treatment of diseases, especially of thromboembolic disorders and/or complications.

Claims

1-10. -10. (canceled)

11. A combination comprising

A) a compound of the formula (I)

12. The combination of claim 11, wherein the compound of the formula (I) is 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide of the formula

13. The combination of claim 11, wherein the antiarrhythmic is an adenosine A1 agonist.

14. The combination of claim 11, wherein the antiarrhythmic is 2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-4-[4-(2-hydroxyethoxy)phenyl]-3,5-pyridinedicarbonitrile of the formula

15. A process for producing the combination of claim 11, wherein one or more oxazolidinones of the formula (I) and one or more antiarrhythmics are combined or prepared in any suitable way.

16. A method for the prophylaxis and/or treatment of a thromboembolic disorder comprising administering a therapeutically effective amount of the combination of claim 11 to a patient in need thereof.

17. A medicament comprising at least one combination as claimed in claim 11 and a further active pharmaceutical ingredient.

18. A medicament comprising at least one combination as claimed in claim 11 and one or more pharmacologically acceptable excipients and/or carriers.

19. A method for the prophylaxis and/or treatment of a thromboembolic disorder comprising administering a therapeutically effective amount of the medicament of claim 18 to a patient in need thereof.

20. A method for the prevention or treatment of cardiogenic thromboembolisms and the prevention, reduction or termination of arrhythmias comprising administering a therapeutically effective amount of the medicament of claim 18 to a patient in need thereof.